Epitope/peptide recognized by hla-a2402-restricted ep-cam-specific ctl and use of the same
AssigneesAichi Prefecture, Otsuka Pharmaceutical Co., Ltd.
InventorKiyotaka KUZUSHIMA
Life of this patent
Estimating the term…
Loading patent…
AssigneesAichi Prefecture, Otsuka Pharmaceutical Co., Ltd.
InventorKiyotaka KUZUSHIMA
Estimating the term…
A peptide consisting essentially of the amino acid sequence represented by SEQ ID NO:1; a peptide consisting essentially of the amino acid sequence represented by SEQ ID NO:2; or a mutant peptide consisting essentially of an amino acid sequence derived from the amino acid sequence represented by SEQ ID NO:1 or 2 by addition, deletion or substitution of one or more amino acids, the peptide being capable of forming a complex with an HLA-A2402 molecule to be recognized by HLA-A2402-restricted cytotoxic T lymphocytes or induce such lymphocytes. Such a peptide is useful as a cancer vaccine for epithelial cancer patients having HLA-A2402.
A method of quantifying HLA-A2402-restricted cytotoxic T lymphocytes in peripheral blood, comprising
A method of quantifying HLA-A2402-restricted cytotoxic T lymphocytes in peripheral blood, comprising
A method of quantifying HLA-A2402-restricted cytotoxic T lymphocytes in peripheral blood, comprising steps (i) and (ii)
A method of quantifying HLA-A2402-restricted cytotoxic T lymphocytes in peripheral blood, comprising steps (i) and (ii)
Dependencies are inferred from the claim text.